Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, People's Republic of China.
J Pharm Biomed Anal. 2011 Apr 28;55(1):230-5. doi: 10.1016/j.jpba.2011.01.009. Epub 2011 Jan 19.
A sensitive and highly selective liquid chromatography tandem mass spectrometric (LC/MS/MS) method was developed and validated for the determination of ciclesonide (CIC) and its active metabolite, desisobutyryl-ciclesonide (des-CIC), in human plasma. Plasma samples were extracted using methyl tert-butyl ether with mifepristone as an internal standard (IS). Separation was carried out on a C(18) column using a mixture of 0.1% formic acid solution and methanol as the mobile phase with linear gradient elution. The detection was operated with positive atmospheric pressure chemical ionization (APCI) by selective multiple reaction monitoring (SRM). The chief benefit of the present method was the high sensitivity, with the lower limit of quantification (LLOQ) as low as 10pg/mL and the linearity ranging from 10 to 10,000pg/mL for both CIC and des-CIC. The method was fully validated and successfully applied to determine CIC and des-CIC simultaneously in human plasma and proved to be suitable for phase I clinical pharmacokinetic study of inhaled ciclesonide in healthy Chinese volunteers.
建立并验证了一种灵敏且高度选择性的液相色谱-串联质谱(LC/MS/MS)法,用于测定人血浆中的环索奈德(CIC)及其活性代谢物去异丁酰基环索奈德(des-CIC)。采用甲基叔丁基醚提取血浆样品,以米非司酮为内标(IS)。采用 C(18)柱,以 0.1%甲酸溶液和甲醇的混合溶液作为流动相,进行线性梯度洗脱,实现分离。检测采用正大气压化学电离(APCI),通过选择的多重反应监测(SRM)进行。本方法的主要优点是灵敏度高,CIC 和 des-CIC 的定量下限(LLOQ)均低至 10pg/mL,线性范围为 10 至 10,000pg/mL。该方法经过全面验证,成功应用于人血浆中 CIC 和 des-CIC 的同时测定,证明适用于健康中国志愿者吸入用环索奈德的 I 期临床药代动力学研究。